mk-6194
Recombinant proteinexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 14, 2021 (NCT04924114)
Timeline
Indications
Mechanism of action
IL2RA agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06821334 | Phase 1 | Apr 23, 2024 | Merck |
| NCT06161116 | Phase 2 | Dec 25, 2023 | Merck |
| NCT06113328 | Phase 2 | Nov 27, 2023 | Merck |
| NCT06649877 | Phase 1 | Mar 20, 2023 | Merck |
| NCT05450198 | Phase 1 | Aug 8, 2022 | Merck |
| NCT04924114 | Phase 1 | Oct 14, 2021 | Merck |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 6 | 6 | 2 | 2021 |
1 organizations
Page 1 / 1